Search - tctmd.com

Displaying 41 - 60 of 87

Sort: Relevancy | Date

Valve Deterioration and Durability Definitions Now Standardized in New Guide

Shelley Wood

September 25, 2017

News Daily News

Newly Proposed Classification of AS Focuses on Baseline Cardiac Damage as Outcome Predictor

L.A. McKeown

July 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

Presentation TVT 2017

An Imaging Perspective of Leaflet Thickening on MDCT: Lessons Learned and Next Steps

Presenter: Martin B. Leon, Hendrik Treede, Philipp Blanke

June 16, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

Presentation TVT 2017

Early Preclinical Experience of Aortic Valve-In-Ring Procedure

Presenter: Juan F. Granada, Martin B. Leon, Gregg W. Stone, Martin Andreas, MD

June 14, 2017

News Features

Valve, Heal Thyself: Pioneers Seek Tissue-Engineered Fix for Faulty, Failing Cardiac Parts

Caitlin E. Cox

June 14, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Shelley Wood

May 02, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News AHA 2016

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

Shelley Wood

November 14, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

Advertisement

Valve Deterioration and Durability Definitions Now Standardized in New Guide

Newly Proposed Classification of AS Focuses on Baseline Cardiac Damage as Outcome Predictor

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

An Imaging Perspective of Leaflet Thickening on MDCT: Lessons Learned and Next Steps

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Early Preclinical Experience of Aortic Valve-In-Ring Procedure

Valve, Heal Thyself: Pioneers Seek Tissue-Engineered Fix for Faulty, Failing Cardiac Parts

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

What TAVR Needs Next . . . and What It’s Getting

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Global TAVR Market Poised to Exceed DES Market by 2025

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content